ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Array BioPharma

1.

Corresponding author: Array BioPharma, array.biopharma@cureus.com

Categories: Oncology

Keywords:

How to cite this poster

Abstract

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study